BCL-XL overexpression enables efficient in vitro erythropoiesis in a human erythroid progenitor cell line

Ex vivo manufacturing of cultured red blood cells (cRBCs) from immortalized erythroid progenitor lines represents a promising cell therapy platform, yet its clinical translation remains hindered by two critical bottlenecks: heavy reliance on expensive recombinant cytokines (EPO and SCF) for expansion, and massive apoptotic loss during terminal erythroid differentiation. To address these challenges, we developed a genetically engineered, BCL-XL–overexpressing human erythroid progenitor cell line (HuBoEP) via lentiviral transduction of the parental human erythroid progenitor cell (HuEPC) line and systematically evaluated its cellular kinetics, viability, and enucleation efficiency. Lentiviral-mediated BCL-XL overexpression did not alter baseline erythroid surface marker expression, confirming phenotypic preservation of the progenitor state. Under cytokine-reduced conditions, HuBoEP cells maintained higher cell numbers and viability than parental HuEPC cells, yielding an approximately 1.6-fold greater expansion in a Reduced Cytokine Expansion Medium (RCEM) containing only 3.3% EPO and 40% SCF of standard concentrations. During a 3-step differentiation protocol, the HuBoEP cells exhibited a 3.39-fold higher cell viability at Day 14 compared to HuEPC cells. A flow-cytometry derived relative enucleated-cell proportion was approximately 2.55-fold higher in HuBoEP cells. After additionally accounting for the relative total cell number, the derived relative total enucleated cell number was approximately 7.19-fold higher in HuBoEP cultures. Crucially, multi-omic and functional characterizations—including RT-qPCR, surface immunophenotyping, Giemsa staining, and hemoglobin-oxygen dissociation assays—confirmed that BCL-XL overexpression preserves physiological lineage maturation and functional integrity without disrupting the intrinsic erythroid differentiation program. Our findings establish BCL-XL not as a surrogate for cytokine signaling, but as an intracellular survival amplifier that mitigates bottleneck-associated cell loss during differentiation. This cellular engineering approach provides a highly translatable platform for the cost-effective and scalable manufacturing of cRBCs, representing a pivotal advancement toward clinical-grade artificial blood production.

Authors

Institutions

Publication Details

Journal
Frontiers in Bioengineering and Biotechnology
Published
2026-11-13
DOI
https://doi.org/10.3389/fbioe.2026.1980062
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

BCL-XL overexpression enables efficient in vitro erythropoiesis in a human erythroid progenitor cell line

Nguyen Vinh Phuoc, Tae Hyeon Hwang, Hyeon Ho Lee, Trần Trà My et al.
Frontiers in Bioengineering and Biotechnology
Hematopoietic Stem Cell Transplantation
article

BCL-XL overexpression enables efficient in vitro erythropoiesis in a human erythroid progenitor cell line

Nguyen Vinh Phuoc, Tae Hyeon Hwang, Hyeon Ho Lee, Trần Trà My, Min Guk Lee, Min Hyuk Kim, Jae Young Kim
article en

Abstract

Ex vivo manufacturing of cultured red blood cells (cRBCs) from immortalized erythroid progenitor lines represents a promising cell therapy platform, yet its clinical translation remains hindered by two critical bottlenecks: heavy reliance on expensive recombinant cytokines (EPO and SCF) for expansion, and massive apoptotic loss during terminal erythroid differentiation. To address these challenges, we developed a genetically engineered, BCL-XL–overexpressing human erythroid progenitor cell line (HuBoEP) via lentiviral transduction of the parental human erythroid progenitor cell (HuEPC) line and systematically evaluated its cellular kinetics, viability, and enucleation efficiency. Lentiviral-mediated BCL-XL overexpression did not alter baseline erythroid surface marker expression, confirming phenotypic preservation of the progenitor state. Under cytokine-reduced conditions, HuBoEP cells maintained higher cell numbers and viability than parental HuEPC cells, yielding an approximately 1.6-fold greater expansion in a Reduced Cytokine Expansion Medium (RCEM) containing only 3.3% EPO and 40% SCF of standard concentrations. During a 3-step differentiation protocol, the HuBoEP cells exhibited a 3.39-fold higher cell viability at Day 14 compared to HuEPC cells. A flow-cytometry derived relative enucleated-cell proportion was approximately 2.55-fold higher in HuBoEP cells. After additionally accounting for the relative total cell number, the derived relative total enucleated cell number was approximately 7.19-fold higher in HuBoEP cultures. Crucially, multi-omic and functional characterizations—including RT-qPCR, surface immunophenotyping, Giemsa staining, and hemoglobin-oxygen dissociation assays—confirmed that BCL-XL overexpression preserves physiological lineage maturation and functional integrity without disrupting the intrinsic erythroid differentiation program. Our findings establish BCL-XL not as a surrogate for cytokine signaling, but as an intracellular survival amplifier that mitigates bottleneck-associated cell loss during differentiation. This cellular engineering approach provides a highly translatable platform for the cost-effective and scalable manufacturing of cRBCs, representing a pivotal advancement toward clinical-grade artificial blood production.

Frontiers in Bioengineering and BiotechnologyVol. 14
Gachon University (KR)
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon